Event Details
In-person event details
Additional Information: Due to the expected popularity of this event early booking is advised. Physical spaces for this meeting are limited and will be allocated on a first come, first served basis.
Agenda
Meet the Speakers
Dr Mockett is a Consultant Child and Adolescent Psychiatrist and a Fellow of the Royal College of Psychiatrists working in all age learning disability service in Lancashire and South Cumbria NHS Trust. He specialises in neurodevelopmental conditions including severe intellectual disability, ASD and ADHD. He has previously worked as the Associate Medical Director for Children’s Services.
Dr Mockett is an active medical educator. He is Training Programme Director in Intellectual Disabilities for Health Education England North West. He contributes to the training of pre-and post-qualification doctors, nurses and psychologists. He has a wide portfolio of presentations, nationally and internationally focusing on audit and research in neurodevelopmental conditions.
Dr Mockett is the Vice Chair North West of the Regional North of England Mental Health Act Approval Panel.
Dr Mockett assesses and treats whole-life neurodevelopmental conditions, ADHD and ASD through his own clinic. Dr Mockett prepares specialist legal reports in neurodevelopmental disorders for CM Medico-legal for both criminal and specialist negligence claims.
Dr Joe Johnson leads the adult ADHD Service of the North West Boroughs NHS Trust. Dr Johnson has over 15 years of Consultant experience of working in acute and community psychiatry, and in prison settings; assessing and managing all common mental health conditions.
Having completed his higher training in psychiatry from the University of Liverpool, he took up a consultant post at the North West Boroughs NHS Trust in February 2005. He set up the Adult ADHD Service at the Trust in 2009, and has since been heading this service, which is one of the biggest ADHD service providers in the North West. He is the North West lead for the national organisation UKAAN (UK Adult ADHD Network).
He has been involved in a multi-centre clinical trial in adult ADHD, fully funded by the University of Manchester. He has delivered ADHD training programmes to a variety of professionals including psychiatrists, GPs, nurses, occupational therapists, probation officers and other practitioners in mental health across the UK and has also been invited to speak at national and international conferences.
Rachel is the Lead Pharmacist for Developmental Paediatrics at Alder Hey Children’s Hospital. She holds a Master of Pharmacy (MPharm) degree and is a qualified independent prescriber. With over seven years of experience in paediatric pharmacy, she has spent the last two years specialising in developmental paediatrics—a field in which she has developed a strong professional interest and commitment.
In her role, she collaborates closely with multidisciplinary teams to optimise medication use and deliver holistic, patient-centred care for children and young people with complex developmental needs. She plays a key role in developing and adapting pharmacy services to better support this patient group, with a focus on improving health outcomes and service accessibility.
Dr. Luisa Sanz-Villanueva is a Child and Adolescent Psychiatrist with nearly three decades of experience in the NHS and over 15 years in private practice. She has worked extensively with children, young people, and adults, including those with learning disabilities, and has held senior leadership roles such as CAMHS Clinical Director.
Passionate about improving understanding of mental health and reducing stigma, Dr. Sanz has a particular interest in neurodevelopmental disorders. She has played an active role in developing ADHD and ASD service provision and was an early adopter of the QB Test for ADHD assessment in 2011, a tool now recognized in NICE guidelines.
In 2017, she founded Mind Yr Life to further advocate for people experiencing mental health difficulties. Through this platform, she regularly publishes articles and contributes to podcasts aimed at raising awareness and broadening knowledge in the field.
Alongside her clinical work, Dr. Sanz is committed to education and research. She frequently gives talks, delivers training, and contributes to national and international research efforts, continuing her mission to improve mental healthcare and understanding.
Dr McCloskey is a Reader of Pharmacy, MPharm Programme Leader, and Co-Lead of the Clinical Pharmacy and Therapeutics Research Group. She is a registered pharmacist of the GPhC (General Pharmaceutical Council) and PSNI (Pharmaceutical Society of Northern Ireland) with a range of experience working across the three main sectors of pharmacy - clinical practice, academia and industry.
Upon successful completion of her pre-registration training, Dr McCloskey returned to Queen's University Belfast and completed a PhD in pharmaceutics where she developed 'self-assembled peptide nanomaterials for the prevention of biomaterial infection'. This was followed by an industry-academia collaborative post-doc between the Royal College of Surgeons in Ireland (RCSI, Dublin) and the Galway-based nebuliser company Aerogen, a global leader in aerosol delivery.
This work was also linked with a national patient focused medical device research centre, CURAM (Centre for Research in Medical Devices) based at The National University of Ireland, Galway. Dr McCloskey is a Fellow of the Royal Pharmaceutical Society and Fellow of HEA. Links are maintained with clinical pharmacy through regular days in practice both in hospital and community settings.
What will the event cover?
Key learning objectives
- To uncover and analyse the challenges associated with transitioning children to adult services including medication options.
- To highlight the challenges of managing sleep in children with ADHD and/or ASD and provide management strategies to improve outcomes.
- To support clinicians in making informed, evidence-based decisions when switching or initiating treatment for ADHD and sleep disorders.
- To evaluate the impact of tablet size on ease of administration and treatment compliance in children and young people.
- To understand the clinical presentation and impact of ADHD across adulthood, including co-occurring mental health conditions.



